Serveur d'exploration MERS - Exploration (Accueil)

Index « Mesh.i » - entrée « Drug Design »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Drug Delivery Systems < Drug Design < Drug Development  Facettes :

List of bibliographic references indexed by Drug Design

Number of relevant bibliographic references: 30.
[0-20] [0 - 20][0 - 30][20-29][20-40]
Ident.Authors (with country if any)Title
000218 (2020) Manisha Prajapat ; Phulen Sarma ; Nishant Shekhar ; Pramod Avti ; Shweta Sinha ; Hardeep Kaur ; Subodh Kumar ; Anusuya Bhattacharyya ; Harish Kumar ; Seema Bansal ; Bikash MedhiDrug targets for corona virus: A systematic review
000463 (2019) Jeong Yoon Lee ; Sojung Bae ; Jinjong MyoungMiddle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design
000501 (2019) Md Mostafijur Rahman [Bangladesh] ; Md Bayejid Hosen [Bangladesh] ; M Zakir Hossain Howlader [Bangladesh] ; Yearul Kabir [Bangladesh]Lead Molecule Prediction and Characterization for Designing MERS-CoV 3C-like Protease Inhibitors: An In silico Approach.
000537 (2019) Hyun Lee ; Jinhong Ren ; Russell P. Pesavento ; Isabel Ojeda ; Amy J. Rice ; Haining Lv ; Youngjin Kwon ; Michael E. JohnsonIdentification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling
000749 (2019) Ayman M S. Ahmed [Égypte] ; Reham A I. Abou-Elkhair [Égypte] ; Alaa M. El-Torky [Égypte] ; Abdalla E A. Hassan [Égypte]3-Trifluoromethylpyrazolones derived nucleosides: Synthesis and antiviral evaluation.
000795 (2018) Anushka C. Galasiti Kankanamalage [États-Unis] ; Yunjeong Kim [États-Unis] ; Vishnu C. Damalanka [États-Unis] ; Athri D. Rathnayake [États-Unis] ; Anthony R. Fehr [États-Unis] ; Nurjahan Mehzabeen [États-Unis] ; Kevin P. Battaile [États-Unis] ; Scott Lovell [États-Unis] ; Gerald H. Lushington [États-Unis] ; Stanley Perlman [États-Unis] ; Kyeong-Ok Chang [États-Unis] ; William C. Groutas [États-Unis]Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element
000A13 (2018) Sayed Sartaj Sohrab [Arabie saoudite] ; Sherif Aly El-Kafrawy [Arabie saoudite] ; Zeenat Mirza [Arabie saoudite] ; Mohammad Amjad Kamal [Arabie saoudite] ; Esam Ibraheem Azhar [Arabie saoudite]Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
000B18 (2017) Jozlyn R. Clasman [États-Unis] ; Yahira M. Báez-Santos [États-Unis] ; Robert C. Mettelman [États-Unis] ; Amornrat O Rien [États-Unis] ; Susan C. Baker [États-Unis] ; Andrew D. Mesecar [États-Unis]X-ray Structure and Enzymatic Activity Profile of a Core Papain-like Protease of MERS Coronavirus with utility for structure-based drug design
000B34 (2017) Woo-Jin Shin [États-Unis] ; Baik Lin Seong [Corée du Sud]Type II transmembrane serine proteases as potential target for anti-influenza drug discovery.
000D08 (2017) Lanying Du [États-Unis] ; Yang Yang [États-Unis] ; Yusen Zhou [République populaire de Chine] ; Lu Lu [République populaire de Chine] ; Fang Li [États-Unis] ; Shibo Jiang [États-Unis]MERS-CoV spike protein: a key target for antivirals.
000E45 (2017) Shan Su [République populaire de Chine] ; Yun Zhu [République populaire de Chine] ; Sheng Ye [République populaire de Chine] ; Qianqian Qi [République populaire de Chine] ; Shuai Xia [République populaire de Chine] ; Zhenxuan Ma [République populaire de Chine] ; Fei Yu [République populaire de Chine] ; Qian Wang [République populaire de Chine] ; Rongguang Zhang [République populaire de Chine] ; Shibo Jiang [République populaire de Chine] ; Lu Lu [République populaire de Chine]Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
001013 (2016) Fenghua Wang [République populaire de Chine] ; Cheng Chen [République populaire de Chine] ; Wenjie Tan [République populaire de Chine] ; Kailin Yang [États-Unis] ; Haitao Yang [République populaire de Chine]Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design
001497 (2015) Xiao-Yun Zeng ; Lu Lu ; Shi-Bo Jiang ; Shu-Wen Liu[Small molecular agents against MERS-CoV infection].
001506 (2015) Shuai Xia ; Qian Wang ; Shu-Wen Liu ; Lu Lu ; Shi-Bo Jiang[Development of peptidic MERS-CoV entry inhibitors].
001624 (2015) Michael Berry [Afrique du Sud] ; Burtram C. Fielding [Afrique du Sud] ; Junaid GamieldienPotential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study
001789 (2015) Thingsoon Jong [Royaume-Uni] ; Ana M. Pérez-L Pez [Royaume-Uni] ; Emma M V. Johansson [Royaume-Uni] ; Annamaria Lilienkampf [Royaume-Uni] ; Mark Bradley [Royaume-Uni]Flow and Microwave-Assisted Synthesis of N-(Triethylene glycol)glycine Oligomers and Their Remarkable Cellular Transporter Activities.
001836 (2015) Hannah L. Peters [États-Unis] ; Dirk Jochmans [Belgique] ; Adriaan H. De Wilde [Pays-Bas] ; Clara C. Posthuma [Pays-Bas] ; Eric J. Snijder [Pays-Bas] ; Johan Neyts [Belgique] ; Katherine L. Seley-Radtke [États-Unis]Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity.
001C50 (2014) Rolf HilgenfeldFrom SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
001E87 (2013) Nan Zhou ; Yun Zhang ; Jin-Chun Zhang ; Ling Feng ; Jin-Ku BaoThe receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development
002A14 (2008) James Thurmond [États-Unis] ; Hyejin Yoon [États-Unis] ; Carla Kuiken [États-Unis] ; Karina Yusim [États-Unis] ; Simon Perkins [États-Unis] ; James Theiler [États-Unis] ; Tanmoy Bhattacharya [États-Unis] ; Bette Korber [États-Unis] ; Will Fischer [États-Unis]Web-based design and evaluation of T-cell vaccine candidates
002B25 (2007) Margaret C. Hsu [États-Unis] ; Jinhwa Lee ; Yoshito KishiSynthetic 3-O-methylmannose-containing polysaccharides (sMMPs): design and synthesis.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Drug Design" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Drug Design" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Drug Design
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021